Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,908 total articles

Arista Networks: Buy the AI-Networking Compounder (Rating Upgrade)

Arista Networks: Buy the AI-Networking Compounder (Rating Upgrade)

Arista is uniquely positioned to capture the next wave of data center networking spend driven by AI. Strong 2025 results, a $5.4B deferred revenue backlog, and FCF of $4.25B support growth guidance and a durable moat. We upgrade to a buy with an entry at $127.50, a target of $177.50, and a stop at $115.00 — horizon: long term (180 trading days).

Intel: A Tactical Long as Helium Scarcity Reorders Foundry Economics

Intel: A Tactical Long as Helium Scarcity Reorders Foundry Economics

Intel (INTC) is a pragmatic long after regaining full control of Fab 34 and amid a scenario where U.S.-Iran friction could tighten helium supply for chip fabs. Combine improved balance-sheet moves, bullish momentum and a unique foundry footprint and the risk/reward supports a targeted trade: entry $51.38, stop $45.00, target $62.00 for a long-term …

Brookfield (BAM): 15% Payout Lift Makes a Yield-Plus Swing Buy at $44.47

Brookfield (BAM): 15% Payout Lift Makes a Yield-Plus Swing Buy at $44.47

Brookfield Asset Management just raised its distribution by 15% and continues to deploy into large deal flow (including a €1.2B Spanish multifamily purchase). At $44.47, the stock yields roughly 4.1% today — the raise pushes that toward ~4.7% — and offers a catalyst-rich setup for a mid-term swing. Valuation on cash-flow multiples is elevated, so p…

Moderna: High-Conviction, High-Risk Buy For mRNA Upside

Moderna: High-Conviction, High-Risk Buy For mRNA Upside

Moderna is trading at roughly $49 and a $19.4B market cap as it pivots from historic COVID revenues toward RSV, flu and oncology mRNA programs. Fundamentals remain challenged - negative EPS, negative free cash flow and a recent multi-billion-dollar legal settlement - but the stock already reflects optimism and a cleared legal overhang. This is a sp…

Fiserv Is Cheap Enough to Own, Not Cheap Enough to Sprint Higher

Fiserv Is Cheap Enough to Own, Not Cheap Enough to Sprint Higher

Fiserv (FISV) trades at single-digit earnings multiples, generates strong free cash flow and just attracted heavyweight interest from Baupost. The stock is deeply discounted relative to cash flow and historical multiples, but operational headwinds and a recent price collapse mean upside will be gradual. This is a long trade for investors willing to…

UnitedHealth: A Timely Buy as Operational Fixes Start to Show

UnitedHealth: A Timely Buy as Operational Fixes Start to Show

UnitedHealth ($UNH) has been punished since last year's peak, but the company still generates healthy free cash flow ($16.1B), pays a 3%+ dividend, and is trading at a reasonable multiple (PE ~21). Technicals and short-interest dynamics favor a recovery. This trade idea lays out an entry, stop and target for a long-term turnaround play over the nex…

Accelerant Holdings: An Underappreciated Insurtech Re-rating Candidate

Accelerant Holdings: An Underappreciated Insurtech Re-rating Candidate

Accelerant Holdings (ARX) operates a data-driven risk exchange that is scaling revenue and moving toward sustained profitability. At $13.42 the stock trades well below prior highs despite 68% revenue growth and an improving operating profile. With modest leverage, attractive EV/Sales and a compact float, this is a tactical long idea for investors w…

MSCI: AI Is Reshaping Workflows, Not Replacing the Franchise

MSCI: AI Is Reshaping Workflows, Not Replacing the Franchise

MSCI sits at a favorable intersection: recurring index and analytics revenue plus growing AI-enabled tools that improve product stickiness and open new revenue channels. Valuation is rich but not disconnected from steady cash flow and predictable renewals. We like a measured long with a defined stop and a 180-day horizon to let contract cycles and …